Quest Partners LLC Acquires Shares of 14,055 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quest Partners LLC acquired a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the third quarter, Holdings Channel reports. The fund acquired 14,055 shares of the life sciences company’s stock, valued at approximately $255,000.

Several other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. boosted its holdings in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC lifted its position in shares of Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares in the last quarter. KBC Group NV boosted its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences in the second quarter valued at approximately $114,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $73,000. Institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

IART has been the subject of several research analyst reports. Citigroup raised their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Bank of America decreased their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. JMP Securities decreased their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $24.00.

Integra LifeSciences Trading Down 2.2 %

Shares of IART stock opened at $23.70 on Wednesday. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42. The company’s fifty day simple moving average is $20.22 and its two-hundred day simple moving average is $24.02. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -263.30, a PEG ratio of 0.80 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.76 EPS. As a group, analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.